Concarlo Therapeutics

Concarlo Therapeutics is a preclinical-stage oncology company focused on developing innovative therapies for drug-resistant cancers. The company aims to transform cancer into a treatable and manageable condition by targeting p27, a natural inhibitor of key cell cycle regulators CDK4/CDK6 and CDK2. Leveraging extensive research, Concarlo seeks to exploit a unique cellular pathway to effectively kill tumor cells rather than merely halting their growth. Its approach emphasizes precision medicine, particularly in managing breast cancer, while also addressing various advanced and orphan cancers such as ovarian and pancreatic cancers. By enhancing drug efficacy and minimizing toxicity, Concarlo Therapeutics aims to provide significant benefits to cancer patients, particularly those facing metastatic disease.